(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 May 2012 (10.05.2012)

PCT

(10) International Publication Number
WO 2012/061833 A1

(51) International Patent Classification:
A61K 31/497 (2006.01) *A61P 7/00* (2006.01)
A61K 9/48 (2006.01)

(21) International Application Number:
PCT/US2011/059643

(22) International Filing Date:
7 November 2011 (07.11.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/410,924 7 November 2010 (07.11.2010) US

(71) Applicant *(for all designated States except US)*: **TARGEGEN, INC.** [US/US]; 9380 Judicial Drive, San Diego, CA 92121 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **JAYAN, Arvind** [GB/US]; 7509 Draper Avenue, Apt. 303, La Jolla, CA 92037 (US). **CACACE, Janice** [US/US]; 527 NE 57th Street, Miami, FL 33137 (US). **TEFFERI, Ayalew** [US/US]; Hematology, Mayo Clinic, 200 First Street S.w., Rochester, MN 55905 (US).

(74) Agents: **ZHOU, Jie** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS

Figure 1 Decrease in Palpable Spleen Size by Cycle
680 mg/day* TG101348 (N = 37)



*Starting dose. Doses (mg/day) Cycle 1, 520-800; Cycles 2-6, 360-680 mg/day.
‡22-47% increase in 3 subjects with drug held for ~2-3 weeks immediately prior to measurement.

(57) **Abstract**: Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-*tert*-butyl-3-[(5-methyl-2-{ [4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4- yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof.

WO 2012/061833 A1